Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGNDZ) Return on Capital Employed (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Return on Capital Employed for 15 consecutive years, with 0.03% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed rose 5.0% to 0.03% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.03% through Dec 2025, up 5.0% year-over-year, with the annual reading at 0.03% for FY2025, 6.0% up from the prior year.
  • Return on Capital Employed hit 0.03% in Q4 2025 for Ligand Pharmaceuticals, up from 0.01% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.09% in Q1 2022 to a low of 0.07% in Q1 2025.
  • Historically, Return on Capital Employed has averaged 0.02% across 5 years, with a median of 0.02% in 2023.
  • Biggest five-year swings in Return on Capital Employed: grew 7bps in 2021 and later decreased -8bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.08% in 2021, then plummeted by -95bps to 0.0% in 2022, then skyrocketed by 317bps to 0.02% in 2023, then plummeted by -258bps to 0.02% in 2024, then surged by 212bps to 0.03% in 2025.
  • Business Quant data shows Return on Capital Employed for LGNDZ at 0.03% in Q4 2025, 0.01% in Q3 2025, and 0.04% in Q2 2025.